{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:13:51Z","timestamp":1759940031728,"version":"3.41.2"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Drugs are the imperial part of modern society, but along with their therapeutic effects, drugs can also cause adverse effects, which can be mild to morbid. Pharmacovigilance is the process of collection, detection, assessment, monitoring and prevention of adverse drug events in both clinical trials as well as in the post-marketing phase. The recent trends in increasing unknown adverse events, known as signals, have raised the need to develop an ideal system for monitoring and detecting the potential signals timely. The process of signal management comprises of techniques to identify individual case safety reports systematically. Automated signal detection is highly based upon the data mining of the spontaneous reporting system such as reports from health care professional, observational studies, medical literature or from social media. If a signal is not managed properly, it can become an identical risk associated with the drug which can be hazardous for the patient safety and may have fatal outcomes which may impact health care system adversely. Once a signal is detected quantitatively, it can be further processed by the signal management team for the qualitative analysis and further evaluations. The main components of automated signal detection are data extraction, data acquisition, data selection, and data analysis and data evaluation. This system must be developed in the correct format and context, which eventually emphasizes the quality of data collected and leads to the optimal decision-making based upon the scientific evaluation.<\/jats:p>","DOI":"10.1093\/bib\/bbaa363","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T13:06:30Z","timestamp":1605013590000},"source":"Crossref","is-referenced-by-count":9,"title":["Automation in signal management in pharmacovigilance\u2014an insight"],"prefix":"10.1093","volume":"22","author":[{"given":"Diksha","family":"Wadhwa","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}]},{"given":"Keshav","family":"Kumar","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}]},{"given":"Sonali","family":"Batra","sequence":"additional","affiliation":[{"name":"Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-4677","authenticated-orcid":false,"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}]}],"member":"286","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"2021072116593687100_ref1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40264-017-0618-y","article-title":"An automated system combining safety signal detection and prioritization from healthcare databases: a pilot study","volume":"41","author":"Arnaud","year":"2018","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"2021072116593687100_ref3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-142-7-200504050-00113","article-title":"The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults","volume":"142","author":"L&#x00E9;vesque","year":"2005","journal-title":"Ann Intern Med"},{"key":"2021072116593687100_ref4","first-page":"18","article-title":"The growing role of signal management in the product life cycle and how optimised pharmacovigilance operations can help","volume":"8","author":"Gandelman","year":"2016","journal-title":"J Clin Stud"},{"key":"2021072116593687100_ref5","article-title":"Essential medicines and health products"},{"key":"2021072116593687100_ref6","article-title":"Signal detection"},{"key":"2021072116593687100_ref7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jbi.2015.02.004","article-title":"Utilizing social media data for pharmacovigilance: a review","volume":"54","author":"Sarker","year":"2015","journal-title":"J Biomed Inform"},{"key":"2021072116593687100_ref8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40290-019-00269-0","article-title":"Artificial intelligence within pharmacovigilance: a means to identify cognitive services and the framework for their validation","volume":"33","author":"Mockute","year":"2019","journal-title":"Pharm Med"},{"key":"2021072116593687100_ref9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/pds.3440","article-title":"Multi-country rapid adverse drug event assessment: the Asian pharmacoepidemiology network (AsPEN) antipsychotic and acute hyperglycaemia study","volume":"22","author":"Pratt","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021072116593687100_ref10","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6947-14-83","article-title":"Adverse drug events with hyperkalaemia during inpatient stays: evaluation of an automated method for retrospective detection in hospital databases","volume":"14","author":"Ficheur","year":"2014","journal-title":"BMC Med Inform Decis Mak"},{"key":"2021072116593687100_ref11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s43441-019-00023-3","article-title":"Utilizing advanced technologies to augment pharmacovigilance systems: challenges and opportunities","volume":"54","author":"Lewis","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"2021072116593687100_ref12","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40264-013-0081-3","article-title":"Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK medicines and healthcare products regulatory agency","volume":"36","author":"Seabroke","year":"2013","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref13","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin Ther"},{"author":"Szmigiel","key":"2021072116593687100_ref14","article-title":"GVP Module IX: Signal management"},{"volume-title":"Human regulatory","key":"2021072116593687100_ref15"},{"key":"2021072116593687100_ref16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat Prod Rep"},{"key":"2021072116593687100_ref17","article-title":"Scientists unravel heparin death mystery"},{"key":"2021072116593687100_ref18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40264-018-0675-x","article-title":"Exploring the potential routine use of electronic healthcare record data to strengthen early signal assessment in UK medicines regulation: proof-of-concept study","volume":"41","author":"Donegan","year":"2018","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/pds.3739","article-title":"Longitudinal medical records as a complement to routine drug safety signal analysis","volume":"24","author":"Star","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021072116593687100_ref20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40264-015-0341-5","article-title":"Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection","volume":"38","author":"Pacurariu","year":"2015","journal-title":"Drug Saf"},{"author":"Vigibase","key":"2021072116593687100_ref21"},{"author":"vigiMethods","key":"2021072116593687100_ref22"},{"key":"2021072116593687100_ref23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/pds.4734","article-title":"Paediatric safety signals identified in VigiBase: methods and results from Uppsala Monitoring Centre","volume":"28","author":"Star","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"year":"2014","key":"2021072116593687100_ref24","article-title":"History of Pharmacovigilance. Mann's Pharmacovigilance"},{"key":"2021072116593687100_ref25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","article-title":"Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?","volume":"36","author":"Coloma","year":"2013","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00002018-200730070-00013","article-title":"Innovations for the future of pharmacovigilance","volume":"30","author":"Almenoff","year":"2007","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"2021072116593687100_ref28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40264-015-0345-1","article-title":"Statistical signal detection as a routine pharmacovigilance practice: effects of periodicity and resignalling criteria on quality and workload","volume":"38","author":"Lerch","year":"2015","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref29","first-page":"517","article-title":"A knowledge management platform for documentation of case reports in pharmacovigilance","volume":"150","author":"Amardeilh","year":"2009","journal-title":"Stud Health Technol Inform"},{"key":"2021072116593687100_ref30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00002018-200730020-00004","article-title":"Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions","volume":"30","author":"Hauben","year":"2007","journal-title":"Drug Saf"},{"volume-title":"EMA\/CHMP\/ICH\/287\/1995","year":"2013","key":"2021072116593687100_ref31"},{"author":"Module IX\u2014Signal management (Rev 1)","key":"2021072116593687100_ref32"},{"key":"2021072116593687100_ref33"},{"volume-title":"Clinical Safety Data Management: Data Elements for Transmission of Individula Case Safety Reports","author":"E2B(R3)","key":"2021072116593687100_ref34"},{"key":"2021072116593687100_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","author":"Bihan","year":"2020","journal-title":"Therapies"},{"key":"2021072116593687100_ref36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1345\/aph.1C515","article-title":"A brief primer on automated signal detection","volume":"37","author":"Hauben","year":"2003","journal-title":"Ann Pharmacother"},{"key":"2021072116593687100_ref37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00002018-200730070-00014","article-title":"Use of triage strategies in the WHO signal-detection process","volume":"30","author":"Lindquist","year":"2007","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance medicines safety database: publicly accessible data for research and public health protection","volume":"41","author":"Postigo","year":"2018","journal-title":"Drug Saf"},{"key":"2021072116593687100_ref39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"2021072116593687100_ref40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/pds.3805","article-title":"Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants","volume":"24","author":"Wong","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021072116593687100_ref41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cpt.320","article-title":"The FDA's sentinel initiative\u2014a comprehensive approach to medical product surveillance","volume":"99","author":"Ball","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2021072116593687100_ref42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cpt.429","article-title":"Successful comparison of US Food and Drug Administration sentinel analysis tools to traditional approaches in quantifying a known drug-adverse event association","volume":"100","author":"Gagne","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2021072116593687100_ref43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40264-014-0194-3","article-title":"A comparison of active adverse event surveillance systems worldwide","volume":"37","author":"Huang","year":"2014","journal-title":"Drug Saf"},{"volume-title":"The Impact of the Sentinel Initiative and FAERS Surveillance System on Consumer Safety","year":"2016","author":"Batra","key":"2021072116593687100_ref44"},{"author":"Eschenbach ACv","key":"2021072116593687100_ref45","article-title":"The sentinel initiative: National Strategy for monitoring medical product safety"},{"volume-title":"Drug Safety and Effectiveness Network","key":"2021072116593687100_ref46"},{"key":"2021072116593687100_ref47","article-title":"Adverse drug reaction database"},{"key":"2021072116593687100_ref48"},{"key":"2021072116593687100_ref49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/pds.2244","article-title":"Pharmacovigilance systems and databases in Korea, Japan, and Taiwan","volume":"20","author":"Kimura","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021072116593687100_ref50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/pds.1902","article-title":"Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database","volume":"19","author":"Choi","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021072116593687100_ref51","first-page":"371","article-title":"Experience implementing electronic health records in three east African countries","volume":"160","author":"Tierney","year":"2010","journal-title":"Stud Health Technol Inform"},{"key":"2021072116593687100_ref52","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1016\/j.vaccine.2016.06.053","article-title":"Monitoring vaccination coverage: defining the role of surveys","volume":"34","author":"Cutts","year":"2016","journal-title":"Vaccine"},{"volume-title":"Pharmacovigilance Automation Has Arrived","year":"2018","author":"Dosanjh","key":"2021072116593687100_ref53"},{"key":"2021072116593687100_ref54"},{"volume-title":"a Rapid News Group Company","year":"2019","author":"Balderson","key":"2021072116593687100_ref55"},{"key":"2021072116593687100_ref56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/DHPS.S7180","article-title":"Information technology in pharmacovigilance: benefits, challenges, and future directions from industry perspectives","volume":"1","author":"Lu","year":"2009","journal-title":"Drug Healthc Patient Saf"},{"key":"2021072116593687100_ref57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40290-019-00320-0","article-title":"Automation opportunities in pharmacovigilance: an industry survey","volume":"34","author":"Ghosh","year":"2020","journal-title":"Pharm Med"},{"key":"2021072116593687100_ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-01001-7","article-title":"Artificial intelligence, real-world automation and the safety of medicines","author":"Bate","year":"2020","journal-title":"Drug Saf"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/4\/bbaa363\/39134043\/bbaa363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/4\/bbaa363\/39134043\/bbaa363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T17:01:30Z","timestamp":1626886890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbaa363\/6041166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa363","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"type":"print","value":"1467-5463"},{"type":"electronic","value":"1477-4054"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2020,12,18]]},"article-number":"bbaa363"}}